WHO approves first malaria treatment for babies
The World Health Organization (WHO) has granted prequalification approval to the first malaria treatment specifically for newborns and infants. This new formulation of artemether-lumefantrine meets international standards for quality, safety, and efficacy.

Briefing Summary
AI-generatedThe World Health Organization (WHO) has granted prequalification approval to the first malaria treatment specifically for newborns and infants. This new formulation of artemether-lumefantrine meets international standards for quality, safety, and efficacy. Previously, infants were treated with medications intended for older children, which posed increased risks of dosage errors and adverse effects. This development marks a significant step in combating malaria, a disease that disproportionately affects young children. The WHO highlighted that this new treatment, alongside other advancements like vaccines and improved mosquito nets, is helping to change the narrative of malaria's impact on communities.
Article analysis
Model · rule-basedKey claims
4 extractedThe prequalification designation indicates that the medicine meets international standards of quality, safety and efficacy.
Artemether-lumefantrine is the first antimalarial formulation designed specifically for the youngest victims.
WHO approved Artemether-lumefantrine, a malaria treatment for newborns and infants.
Infants have been treated with formulations intended for older children, carrying risks.